🇺🇸 FDA
Pipeline program

PROMETHAZINE , DIPHENHYDRAMINE , CETIRIZINE , DEXCHLORPHENIRAMINE , PARACETAMOL , SAR443579

TCD17197

Phase 2 small_molecule active

Quick answer

PROMETHAZINE , DIPHENHYDRAMINE , CETIRIZINE , DEXCHLORPHENIRAMINE , PARACETAMOL , SAR443579 for Acute lymphocytic leukaemia- Acute myeloid leukaemia refractory - Myelodysplastic syndrome - Blastic plasmacytoid dendritic cell neoplasia is a Phase 2 program (small_molecule) at Sanofi Pharma Bristol-Myers Squibb with 1 ClinicalTrials.gov record(s).

Program details

Company
Sanofi Pharma Bristol-Myers Squibb
Indication
Acute lymphocytic leukaemia- Acute myeloid leukaemia refractory - Myelodysplastic syndrome - Blastic plasmacytoid dendritic cell neoplasia
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials